Processa Pharmaceuticals, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Processa Pharmaceuticals, Inc. (PCSA) reported Net Income (Loss) Available to Common Stockholders, Basic of -$3.27 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-14
- Processa Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$3.27M.
- Processa Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$3.38M.
- Processa Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$3.36M.
- Processa Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$3.44M.
- Processa Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2025 was -$13.56M.
- Processa Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2024 was -$11.85M.
- Processa Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was -$11.12M.
- Processa Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was -$27.42M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 27 month | Net Income (Loss) Available to Common Stockholders, Basic 30 month | Net Income (Loss) Available to Common Stockholders, Basic 33 month | Net Income (Loss) Available to Common Stockholders, Basic 36 month |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$3.27M 10-Q · filed 2026-08-14 | -$6.64M 10-Q · filed 2026-08-14 | -$10.00M derived: sum of 3 quarters · filed 2026-08-14 | -$13.44M derived: sum of 4 quarters · filed 2026-08-14 | |||||
| 2026-03-31 | -$3.38M 10-Q · filed 2026-05-07 | -$6.74M derived: sum of 2 quarters · filed 2026-05-07 | -$10.17M derived: sum of 3 quarters · filed 2026-05-07 | -$14.11M derived: sum of 4 quarters · filed 2026-08-14 | |||||
| 2025-12-31 | -$3.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$6.80M derived: sum of 2 quarters · filed 2026-03-18 | -$10.73M derived: sum of 3 quarters · filed 2026-08-14 | -$13.56M 10-K · filed 2026-03-18 | |||||
| 2025-09-30 | -$3.44M 10-Q · filed 2025-11-06 | -$7.37M derived: sum of 2 quarters · filed 2026-08-14 | -$10.20M 10-Q · filed 2025-11-06 | -$12.93M derived: sum of 4 quarters · filed 2026-08-14 | |||||
| 2025-06-30 | -$3.93M 10-Q · filed 2026-08-14 | -$6.77M 10-Q · filed 2026-08-14 | -$9.50M derived: sum of 3 quarters · filed 2026-08-14 | -$12.88M derived: sum of 4 quarters · filed 2026-08-14 | |||||
| 2025-03-31 | -$2.83M 10-Q · filed 2026-05-07 | -$5.56M derived: sum of 2 quarters · filed 2026-05-07 | -$8.95M derived: sum of 3 quarters · filed 2026-05-07 | -$11.96M derived: sum of 4 quarters · filed 2026-05-07 | |||||
| 2024-12-31 | -$2.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$6.11M derived: sum of 2 quarters · filed 2026-03-18 | -$9.12M derived: sum of 3 quarters · filed 2026-03-18 | -$11.85M 10-K · filed 2026-03-18 | |||||
| 2024-09-30 | -$3.38M 10-Q · filed 2025-11-06 | -$6.40M derived: sum of 2 quarters · filed 2025-11-06 | -$9.12M 10-Q · filed 2025-11-06 | -$11.53M derived: sum of 4 quarters · filed 2025-11-06 | |||||
| 2024-06-30 | -$3.01M 10-Q · filed 2025-08-07 | -$5.74M 10-Q · filed 2025-08-07 | -$8.14M derived: sum of 3 quarters · filed 2025-08-07 | -$10.22M derived: sum of 4 quarters · filed 2025-08-07 | |||||
| 2024-03-31 | -$2.73M 10-Q · filed 2025-05-08 | -$5.13M derived: sum of 2 quarters · filed 2025-05-08 | -$7.21M derived: sum of 3 quarters · filed 2025-05-08 | -$9.83M derived: sum of 4 quarters · filed 2025-05-08 | |||||
| 2023-12-31 | -$2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$4.49M derived: sum of 2 quarters · filed 2025-03-20 | -$7.10M derived: sum of 3 quarters · filed 2025-03-20 | -$11.12M 10-K · filed 2025-03-20 | |||||
| 2023-09-30 | -$2.08M 10-Q · filed 2024-10-30 | -$4.69M derived: sum of 2 quarters · filed 2024-10-30 | -$8.72M 10-Q · filed 2024-10-30 | ||||||
| 2023-06-30 | -$2.61M 10-Q · filed 2024-08-13 | -$6.63M 10-Q · filed 2024-08-13 | |||||||
| 2023-03-31 | -$4.02M 10-Q · filed 2024-05-10 | ||||||||
| 2022-12-31 | -$27.42M 10-K · filed 2024-03-29 | ||||||||
| 2021-12-31 | -$11.43M 10-K · filed 2022-03-30 | ||||||||
| 2020-12-31 | -$19.04M 10-K · filed 2022-03-30 | -$14.47M 10-K · filed 2021-03-25 | |||||||
| 2019-12-31 | -$3.86M 10-K · filed 2021-03-25 | ||||||||
| 2018-12-31 | -$3.77M 10-K · filed 2020-03-06 | ||||||||
| 2017-09-30 | -$204.41K 10-Q · filed 2017-11-20 | -$257.97K derived: sum of 2 quarters · filed 2017-11-20 | -$322.89K 10-Q · filed 2017-11-20 | -$445.83K derived: sum of 4 quarters · filed 2017-11-20 | |||||
| 2017-06-30 | -$53.56K 10-Q · filed 2017-10-04 | -$139.77K 10-Q · filed 2017-10-04 | -$241.42K derived: sum of 3 quarters · filed 2017-10-04 | -$320.58K derived: sum of 4 quarters · filed 2017-11-20 | |||||
| 2017-03-31 | -$86.22K 10-Q · filed 2017-10-04 | -$187.86K derived: sum of 2 quarters · filed 2017-10-04 | -$267.02K derived: sum of 3 quarters · filed 2017-11-20 | -$320.93K derived: sum of 4 quarters · filed 2017-11-20 | |||||
| 2016-12-31 | -$101.65K derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-25 | -$180.81K derived: sum of 2 quarters · filed 2017-11-20 | -$234.71K derived: sum of 3 quarters · filed 2017-11-20 | -$379.04K 10-K · filed 2017-09-25 | |||||
| 2016-09-30 | -$79.16K 10-Q · filed 2017-11-20 | -$133.06K derived: sum of 2 quarters · filed 2017-11-20 | -$277.39K 10-Q · filed 2017-11-20 | -$650.98K derived: sum of 4 quarters · filed 2017-11-20 | |||||
| 2016-06-30 | -$53.91K 10-Q · filed 2017-10-04 | -$198.24K 10-Q · filed 2017-10-04 | -$571.83K derived: sum of 3 quarters · filed 2017-10-04 | -$878.39K derived: sum of 4 quarters · filed 2017-10-04 | |||||
| 2016-03-31 | -$144.33K 10-Q · filed 2017-10-04 | -$517.92K derived: sum of 2 quarters · filed 2017-10-04 | -$824.49K derived: sum of 3 quarters · filed 2017-10-04 | -$2.89M derived: sum of 4 quarters · filed 2017-10-04 | |||||
| 2015-12-31 | -$373.59K derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-25 | -$680.16K derived: sum of 2 quarters · filed 2017-09-25 | -$2.74M derived: sum of 3 quarters · filed 2017-09-25 | -$3.40M 10-K · filed 2017-09-25 | |||||
| 2015-09-30 | -$306.57K 10-Q · filed 2017-09-08 | -$2.37M derived: sum of 2 quarters · filed 2017-09-08 | -$3.02M 10-Q · filed 2017-09-08 | -$5.93M derived: sum of 4 quarters · filed 2017-09-08 | |||||
| 2015-06-30 | -$2.06M 10-Q · filed 2017-08-30 | -$2.72M 10-Q · filed 2017-08-30 | -$5.62M derived: sum of 3 quarters · filed 2017-08-30 | -$6.49M derived: sum of 4 quarters · filed 2017-08-30 | |||||
| 2015-03-31 | -$655.20K 10-Q · filed 2017-08-07 | -$3.56M derived: sum of 2 quarters · filed 2017-08-07 | -$4.43M derived: sum of 3 quarters · filed 2017-08-07 | -$5.34M derived: sum of 4 quarters · filed 2017-08-07 | |||||
| 2014-12-31 | -$2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2017-06-19 | -$3.77M derived: sum of 2 quarters · filed 2017-06-19 | -$4.69M derived: sum of 3 quarters · filed 2017-06-19 | -$6.03M 10-K · filed 2017-06-19 | |||||
| 2014-09-30 | -$871.84K 10-Q · filed 2015-12-01 | -$1.78M derived: sum of 2 quarters · filed 2015-12-01 | -$3.13M 10-Q · filed 2015-12-01 | -$3.76M derived: sum of 4 quarters · filed 2015-12-01 | |||||
| 2014-06-30 | -$912.35K 10-Q · filed 2015-08-19 | -$2.25M 10-Q · filed 2015-08-19 | -$2.88M derived: sum of 3 quarters · filed 2015-08-19 | -$3.82M derived: sum of 4 quarters · filed 2015-08-19 | |||||
| 2014-03-31 | -$1.38M 10-Q · filed 2015-05-15 | -$1.97M derived: sum of 2 quarters · filed 2015-05-15 | -$2.91M derived: sum of 3 quarters · filed 2015-05-15 | -$3.67M derived: sum of 4 quarters · filed 2015-05-15 | -$8.26M 10-Q · filed 2014-05-14 | ||||
| 2013-12-31 | -$589.63K derived: 10-K 12 month − 10-Q 9 month · filed 2015-04-14 | -$1.52M derived: sum of 2 quarters · filed 2015-04-14 | -$2.29M derived: sum of 3 quarters · filed 2015-04-14 | -$3.09M 10-K · filed 2015-04-14 | -$6.88M 10-K · filed 2014-03-27 | ||||
| 2013-09-30 | -$932.60K 10-Q · filed 2014-11-13 | -$1.70M derived: sum of 2 quarters · filed 2014-11-13 | -$2.50M 10-Q · filed 2014-11-13 | -$3.50M derived: sum of 4 quarters · filed 2014-11-13 | -$5.93M 10-Q · filed 2013-11-08 | ||||
| 2013-06-30 | -$768.36K 10-Q · filed 2014-08-19 | -$1.63M 10-Q · filed 2014-08-19 | -$2.57M derived: sum of 3 quarters · filed 2014-08-19 | -$3.26M derived: sum of 4 quarters · filed 2014-08-19 | -$5.17M 10-Q/A · filed 2013-09-06 | ||||
| 2013-03-31 | -$915.31K 10-Q · filed 2014-05-14 | -$1.80M derived: sum of 2 quarters · filed 2014-05-14 | -$2.49M derived: sum of 3 quarters · filed 2014-05-14 | -$3.03M derived: sum of 4 quarters · filed 2014-05-14 | |||||
| 2012-12-31 | -$883.17K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-27 | -$1.57M derived: sum of 2 quarters · filed 2014-03-27 | -$2.12M derived: sum of 3 quarters · filed 2014-03-27 | -$2.77M 10-K · filed 2014-03-27 | |||||
| 2012-09-30 | -$691.59K 10-Q · filed 2013-11-08 | -$1.24M derived: sum of 2 quarters · filed 2013-11-08 | -$1.89M 10-Q · filed 2013-11-08 | ||||||
| 2012-06-30 | -$544.70K 10-Q/A · filed 2013-09-06 | -$1.19M 10-Q/A · filed 2013-09-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |